[2]
Khalsa, K.P.S.; Tierra, M. The Way of Ayurvedic Herbs; Lotus Press: Twin Lakes, WI, USA, 2008.
[3]
Skenderi, G. Herbal Vade Mecum Rutherford; Herbacy Press: Rutherford, NJ, USA, 2003.
[5]
Suresh, D.; Chaudhari, Y.S.; Borole, P.; Mishra, P.T.; Shenghani, K.; Duvvuri, P. Degradation studies of curcumin. Int. J. Pharma Res. Rev., 2013, 3, 50-55.
[8]
Shaveta, S.; Shweta, P.; Upendra, J. Development and evaluation of topical gel of curcumin from different combination of polymers for-mulation and evaluation of herbal gel. Int. J. Pharm. Pharm. Sci., 2012, 4, 452-456.
[29]
Chattopadhyay, I.; Biswas, K.; Bandyopadhyay, U.; Banerjee, R.K. Turmeric and curcumin: Biological actions and medicinal applications. Curr. Sci., 2004, 87(1), 44-53.
[42]
Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010: Results by Cause 1990-2010; IHME: Seattle, 2012.
[50]
Alshami, M.A. Clinical profile of psoriasis in Yemen, a 4-year retrospective study of 241 patients. J. Eur. Acad. Dermatol. Venereol., 2010, 24(4), 14.
[51]
Falodun, O.A. Characteristics of patients with psoriasis seen at the dermatology clinic of a tertiary hospital in Nigeria: A 4-year review. J. Eur. Acad. Dermatol. Venereol., 2013, 27(4), 2008-2012.
[61]
Kupczyk, P.; Reich, A. Hołysz, M.; Szepietowski, J. Expression of MOR and KOR opioid receptors and OPRK1 gene in psoriasis pa-tients. Przegl. Dermatol., 2012, 99, 467-468.
[65]
Raychaudhuri, S.P.; Gross, J. Psoriasis risk factors: Role of lifestyle practices. Cutis, 2000, 66(5), 348-352.
[136]
Sondergaard, J.; Wadskov, S.; Jensen, H.A.; Mikkelsen, H.I. Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm. Venereol., 1976, 56(3), 239-243.
[143]
Sowmya, C.; Lavakumar, V.; Venkateshan, N.; Anitha, P.; Senthilnathan, B. Current trends in treatment and management of psoriasis: An updated review. Int. Res. J. Pharm, 2018, 9(3), 6-16.
[162]
Klein, U.; Liang, E.; Vogel, B.; Kolbinger, F.; Bruin, G.; Lloyd, P. Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients. J. Invest. Dermatol., 2013, 133(Suppl. 1), S172.
[186]
Marchiani, A.; Rozzo, C.; Fadda, A.; Delogu, G.; Ruzza, P. Curcumin and curcumin-like molecules: From spice to drugs. Curr. Med. Chem., 2014, 21, 204-222.
[209]
Mao, K.L.; Fan, Z.L.; Yuan, J.D.; Chen, P.P.; Yang, J.J.; Xu, J. ZhuGe, D.L.; Jin, B.H.; Zhu, Q.Y.; Shen, B.X.; Sohawon, Y.; Zhao, Y.Z.; Xu, H.L. Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Colloids Surf. B Biointerfaces, 2017, 160, 704-714.
[226]
Sun, L.; Liu, Z.; Wang, L.; Cun, D.; Henry, H.Y. Tong, Yan,R.U.; Chen, X.; Wang, R.; Zheng, Y. Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J. Control. Release, 2017, 03, 385.